<DOC>
	<DOC>NCT00394563</DOC>
	<brief_summary>The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.</brief_summary>
	<brief_title>A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or nonpregnant female aged 4075 with chronic moderate to severe knee pain due to OA (scoring 50 out of 100 on a visual analog scale on knee pain). Subjects must meet one of the following: unwilling to take nonopiate pain medications, or for whom nonopiate pain medications have failed, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery History or symptoms of autoimmune disorders, cancer within the last 5 years except for cutaneous basal cell or squamous cell cancer resolved by excision, allergic reaction to monoclonal antibodies or IgGfusion proteins, Hepatitis B, C or HIV, drug abuse, fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral treatment or insulin, clinically significant neurological disease or clinically significant psychiatric disorders</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>osteoarthritis monoclonal antibody</keyword>
</DOC>